MARY GILMORE: Open Payments
NPI 1679204697 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$448 in 17 payments from 8 companies in 2025. Trend: 2023 $250 · 2024 $165 · 2025 $448
Food & beverage: $448
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 1 | $174 |
| Novo Nordisk Inc | 4 | $74 |
| Amgen Inc. | 4 | $60 |
| Novartis Pharmaceuticals Corporation | 3 | $48 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| Lilly USA, LLC | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Merck Sharp & Dohme LLC | 1 | $14 |
Products named: NAVITOR, Wegovy, REPATHA, LEQVIO, Kerendia, MOUNJARO, CAMZYOS, VERQUVO.
Industry payments across KS — which companies pay providers there.
